- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07695493
Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis (PREVI)
An Open-label Randomized Trial Evaluating the Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The HIV/AIDS epidemic remains uncontrolled in France, with approximately 5,000 to 6,000 new cases reported each year. Since January 2016, HIV pre-exposure prophylaxis (PrEP)-which involves taking a single oral tablet containing two antiretroviral drugs-has been available in France. The effectiveness of this PrEP has been demonstrated, with a relative reduction in HIV incidence of nearly 97% when PrEP is taken correctly.
However, only nearly 50,000 people are using PrEP in France in 2024, which is far short of the targets needed to control the epidemic. Indeed, the population of men who have sex with men (MSM) at risk of HIV infection is estimated at over 200,000, and the number of heterosexuals on PrEP is negligible, even though 40% of new HIV diagnoses involve heterosexuals from countries with high prevalence (Sub-Saharan Africa).
Furthermore, these 50,000 people on PrEP represent only 64% of the >120,000 people who have started PrEP since 2016, indicating that many have discontinued this prophylaxis over time. One of the challenges in implementing PrEP stems from the small number of trained hospital and primary care physicians and their limited time availability to provide a PrEP care.
Since 2022, PrEP training programs in medical settings, involving nurses, have been implemented to train them to monitore people on PrEP. This involvement of nurses would help increase the availability of PrEP, free up doctors' time for complex cases, and enhance the value of nursing work.
However, there has been no evaluation of this care provided by nurses to people on PrEP in terms of quality, acceptability, satisfaction among people on PrEP, nurses, and doctors, or its cost-effectiveness.
The aim of our study is therefore to assess whether the care provided to subjects on PrEP by these nurses is as good, well-accepted, and satisfactory for subjects and caregivers as it would be if the care were provided solely by physicians.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jérôme Lambert, MD PhD
- Número de teléfono: +33 0142499742
- Correo electrónico: jerome.lambert@u-paris.fr
Copia de seguridad de contactos de estudio
- Nombre: Bénédicte Loze, Nurse
- Número de teléfono: +33 01.42.49.48.52
- Correo electrónico: benedicte.loze@aphp.fr
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Male sex assigned at birth, aged ≥ 18 years
- Individual at risk of HIV infection
- Currently receiving PrEP care and willing to continue follow-up in a hospital setting
- Receiving care at a hospital setting by a physician and not objecting to follow-up by a nurse
- Having received complete information about the study and having provided a free written informed consent
- Affiliated with a social security system (beneficiary or entitled individual) or covered by State Medical Aid (AME).
Exclusion Criteria:
- Individual with confirmed HIV infection
- Currently receiving nurse care in a hospital setting
- Having renal impairment (creatinine clearance < 60 mL/min)
- Unable to provide informed consent
- Not affiliated with a social security system or not covered by State Medical Aid (AME)
- Under legal guardianship or curatorship
- Deprived of liberty by judicial or administrative decision, or individuals receiving psychiatric care under Article L1121-6 of the French Public Health Code
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Follow-up visits for PrEP prescription conducted by a physician.
|
Monitoring of PrEP by physicians
|
|
Experimental: Follow-up visits for PrEP prescription conducted by a nurse under the same conditions.
|
Monitoring of PrEP by nurses
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Compliance to PrEP
Periodo de tiempo: Up to 12 months
|
Compliance to PrEP is defined by a composite criterion comprising:
|
Up to 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Occurrence of sexually transmitted infection (STI)
Periodo de tiempo: At baseline
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At baseline
|
|
Occurrence of sexually transmitted infection (STI)
Periodo de tiempo: At 6 months
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At 6 months
|
|
Occurrence of sexually transmitted infection (STI)
Periodo de tiempo: At 12 months
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At 12 months
|
|
Tolerability of PrEP
Periodo de tiempo: At baseline
|
Plasma creatine level
|
At baseline
|
|
Tolerability of PrEP
Periodo de tiempo: At 6 months
|
Plasma creatine level
|
At 6 months
|
|
Tolerability of PrEP
Periodo de tiempo: At 12 months
|
Plasma creatine level
|
At 12 months
|
|
PrEP adherence
Periodo de tiempo: At 12 months
|
Number of patient visits completed during the year and Tenofovir diphosphate concentrations
|
At 12 months
|
|
Treatment acceptability among participants
Periodo de tiempo: Up to 12 months
|
Number of participants who discontinued follow-up and reasons for discontinuation
|
Up to 12 months
|
|
Incidence of HIV infection
Periodo de tiempo: Up to 12 months
|
HIV infection during follow up (positive serology or HIV RNA)
|
Up to 12 months
|
|
Cost of care
Periodo de tiempo: Up to 12 months
|
From the perspectives of the healthcare system, patients, and health insurance : Incremental or decremental cost-effectiveness ratio (Cost per patient, Time spent in consultations, Number of prescribed labs and tests, and Number and duration of any hospitalizations…)
|
Up to 12 months
|
|
Patient and caregiver satisfaction
Periodo de tiempo: At 12 months
|
Focus groups
|
At 12 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones transmitidas por la sangre
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del sistema inmunológico
- Infecciones
- Infecciones por virus de ARN
- Enfermedades virales
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Infecciones por VIH
Otros números de identificación del estudio
- APHP230860
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .